A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also deserves some restraint: this is healthcare, not a scoreboard for shiny hardware.
The Market Estimate Has Real Weight
Wissen Research puts the global digital diabetes management market at $20.9 billion in 2026 and projects $34.4 billion by 2031, a 10.5% compound annual growth rate. Forecasts are forecasts, not promissory notes, and plenty of market studies carry more confidence than precision. Still, the direction is hard to dismiss when the underlying patient population is so large. The International Diabetes Federation estimates 589 million adults lived with diabetes in 2024 and expects 853 million by 2050.
That is a grim public-health backdrop, not a cheerleading statistic. Yet it explains why continuous glucose monitoring, connected pumps, smart pens and data platforms have become strategically important. The commercial prize is recurring sensor and disposable demand, plus the possibility that software and data services make a device ecosystem harder to leave.
Type 2 Is Where the Argument Gets Serious
For years, the most sophisticated connected tools were largely built around Type 1 diabetes. The much bigger opening is Type 2, particularly insulin-treated people and, increasingly, people who do not use insulin. FDA actions in 2024 cleared Dexcom's Stelo and Abbott's Lingo for over-the-counter use, while Abbott's Libre Rio was cleared for adults with Type 2 diabetes not using insulin. In June 2026, Stelo's clearance was extended to children aged two and older who do not use insulin.
The clinical rationale is encouraging but should not be oversold. A 2025 randomized trial involving 72 adults with Type 2 diabetes who were not taking insulin found CGM users improved time-in-range from 46% to 72% over six months and reduced HbA1c by 1.3 percentage points. That is meaningful. It is also a small study, and larger confirmation matters before anybody starts treating one result as the whole case.
Integration Is Becoming the Product
The old device-by-device view is getting stale. Remote diabetes data uploads surpassed in-clinic uploads in early 2024 and were roughly 1.5 times higher by year-end, according to Glooko's 2025 report. Patients and care teams increasingly need sensor data, insulin delivery and coaching tools to cooperate without making the user play unpaid systems integrator.
That is why interoperability has genuine business significance. Tandem Diabetes Care received Health Canada approvals in November 2026 for its t:slim X2 pump with Control-IQ+ technology, including compatibility with Abbott's FreeStyle Libre 3 Plus sensor. Commercial availability is expected in the second quarter of 2027. Medtronic's MiniMed Go pairs its InPen smart pen with Abbott's Instinct sensor, while Insulet has been pushing Omnipod Discover, a web-based data platform for Omnipod 5 users, caregivers and clinicians.
Each announcement sounds incremental in isolation. Together, they show a market moving toward ecosystems. Abbott's multi-year partnership with Google Health, announced in August 2026, similarly aims to combine Lingo glucose insights with AI-powered health technology. The opportunity is obvious; so are the privacy, cybersecurity and evidence questions around turning health data into advice.
Recurring Revenue Meets a Hard Affordability Wall
Devices led the market in 2025, supported by the repeat purchase cycle for sensors and other consumables. Abbott reported $7.6 billion in CGM sales that year, Dexcom reported $4.66 billion in revenue, up 16%, and Insulet reported $2.67 billion in Omnipod revenue, up 31.6%. Those are serious numbers, not a niche wellness fad.
But diabetes technology has an ugly access problem. A 2025 study across six low- and middle-income countries found sensors cost roughly $88 to $107 each, with a month's supply requiring 15 to 65 days of wages. Medicare coverage in the United States also remains tied to insulin treatment or documented problematic hypoglycemia. A market can grow briskly and still leave a great many people out; both things can be true at once.
- Watch reimbursement expansion, because coverage often determines adoption more than product polish.
- Watch manufacturing quality and regulatory compliance as over-the-counter CGM reaches a broader public.
- Watch whether software reduces clinical workload rather than simply adding another dashboard.
Scale Will Not Automatically Pick the Winners
North America remains the leading region, while Asia Pacific is identified as the fastest-growing. The long runway in Asia is compelling: the Western Pacific had about 215.4 million adults with diabetes in 2024, and South-East Asia had another 106.9 million. But broad need does not magically solve pricing, connectivity, local reimbursement or digital literacy.
The durable winners should be the companies that make accurate monitoring affordable, connect cleanly with other systems and prove that the information improves care. Fancy algorithms are fine. Dependable access is better. In this corner of medtech, trust gets built one sensor, one reimbursement decision and one workable patient experience at a time.